BB-rel@ldeleger:BB-rel-9745160 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-ost-19-BB-rel-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T1 0-109 Title denotes New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection.
T7 59-73 Habitat denotes duodenal ulcer
T6 59-67 Habitat denotes duodenal
T8 79-98 Microorganism denotes Helicobacter pylori
T2 110-656 Paragraph denotes Antimicrobial therapy is the recommended treatment for duodenal ulcer associated with Helicobacter pylori infection. The eradication of bismuth-based triple therapy with bismuth subcitrate, metronidazole and amoxicillin is limited by low compliance, drug resistance and side-effects. Two-week proton pump inhibitor (PPI)-based triple therapy has a higher eradication rate but is costly. This study was designed to compare the efficacy, patient compliance and cost of short-term PPI-based triple therapy with those of bismuth-based triple therapy.
T9 165-179 Habitat denotes duodenal ulcer
T10 165-173 Habitat denotes duodenal
T11 196-215 Microorganism denotes Helicobacter pylori
T12 360-375 Phenotype denotes drug resistance
T13 546-553 Habitat denotes patient
T3 657-1547 Paragraph denotes Ninety patients with active duodenal ulcer disease and H pylori infection, proven with the 13C-urea breath test and CLO test (Campylobacter-like organism test) were treated randomly in three therapeutic groups: Group A, DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days; Group B, omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days; Group C, omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days. Nizatidine 150 mg twice a day was given continuously following the end of anti-H pylori therapy for each group. Two months later, endoscopy, the CLO test and 13C-urea breath test were repeated to assess the eradication rate of H pylori and the ulcer-healing rate. Drug tolerance was evaluated by patients themselves by daily recording of any side-effects.
T14 664-730 Habitat denotes patients with active duodenal ulcer disease and H pylori infection
T15 685-699 Habitat denotes duodenal ulcer
T16 685-693 Habitat denotes duodenal
T17 712-720 Microorganism denotes H pylori
T18 783-796 Microorganism denotes Campylobacter
T19 1271-1279 Microorganism denotes H pylori
T20 1419-1427 Microorganism denotes H pylori
T21 1436-1441 Habitat denotes ulcer
T22 1488-1496 Habitat denotes patients
T4 1548-2241 Paragraph denotes Eighty-four patients completed the entire course of therapy and evaluation for H pylori infection. The H pylori eradication rates in Groups A, B and C were 75% (21/28), 93% (26/28) and 89% (25/28), respectively (p = 0.466). The ulcer healing rate was 86% (24/28) in Group A and 89% (25/28) in Groups B and C (p = 0.764). A total of 74 patients (88%) were free from symptoms at the end of the triple therapy. Symptom relief was faster in patients with PPI-based triple therapy (Groups B and C) (days 3 and 4) than for patients with bismuth-based triple therapy (day 5). The cost of Group C therapy was lower than that for Groups A and B. There were no major side-effects in any of the patients.
T23 1560-1568 Habitat denotes patients
T24 1627-1635 Microorganism denotes H pylori
T25 1651-1659 Microorganism denotes H pylori
T26 1776-1781 Habitat denotes ulcer
T27 1883-1891 Habitat denotes patients
T28 1985-2023 Habitat denotes patients with PPI-based triple therapy
T29 2065-2107 Habitat denotes patients with bismuth-based triple therapy
T30 2232-2240 Habitat denotes patients
T5 2242-2579 Paragraph denotes One-week triple therapy with omeprazole, clarithromycin and metronidazole is highly effected for the eradication of H pylori. A therapeutic regime of one week's duration with lower cost, good compliance and mild side-effects may offer a good choice for treatment of duodenal ulcer associated with H pylori infection in clinical practice.
T31 2358-2366 Microorganism denotes H pylori
T33 2508-2522 Habitat denotes duodenal ulcer
T32 2508-2516 Habitat denotes duodenal
T34 2539-2547 Microorganism denotes H pylori
E1 79-98 Lives_In denotes Helicobacter pylori
E2 79-98 Lives_In denotes Helicobacter pylori
E3 196-215 Lives_In denotes Helicobacter pylori
E4 196-215 Lives_In denotes Helicobacter pylori
E5 712-720 Lives_In denotes H pylori
E6 712-720 Lives_In denotes H pylori
E7 712-720 Lives_In denotes H pylori
E8 2539-2547 Lives_In denotes H pylori
E9 2539-2547 Lives_In denotes H pylori
R1 E1 T8 Microorganism Helicobacter pylori,Helicobacter pylori
R2 E1 T6 Location Helicobacter pylori,duodenal
R3 E2 T8 Microorganism Helicobacter pylori,Helicobacter pylori
R4 E2 T7 Location Helicobacter pylori,duodenal ulcer
R5 E3 T11 Microorganism Helicobacter pylori,Helicobacter pylori
R6 E3 T9 Location Helicobacter pylori,duodenal ulcer
R7 E4 T11 Microorganism Helicobacter pylori,Helicobacter pylori
R8 E4 T10 Location Helicobacter pylori,duodenal
R9 E5 T17 Microorganism H pylori,H pylori
R10 E5 T16 Location H pylori,duodenal
R11 E6 T17 Microorganism H pylori,H pylori
R12 E6 T15 Location H pylori,duodenal ulcer
R13 E7 T17 Microorganism H pylori,H pylori
R14 E7 T14 Location H pylori,patients with active duodenal ulcer disease and H pylori infection
R15 E8 T34 Microorganism H pylori,H pylori
R16 E8 T33 Location H pylori,duodenal ulcer
R17 E9 T34 Microorganism H pylori,H pylori
R18 E9 T32 Location H pylori,duodenal